Study of Sequential Perfusion of Liver Grafts to Prevent Nonanastomotic Biliary Strictures After Liver Transplantation
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The study was designed to investigate whether, compared with conventional sole perfusion with high-viscosity solution of University of Wisconsin (UW), sequential perfusion of liver grafts with low-viscosity and high-viscosity preservation solutions could further decrease the incidence of nonanastomotic biliary strictures (NAS) after liver transplantation.
| Condition | Intervention |
|---|---|
|
Liver Transplantation Transplant Recipient |
Procedure: sequential perfusion with ipv Ross solution and UW solution Procedure: sole perfusion with UW solution |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Study of Sequential Perfusion of Liver Grafts With Low-viscosity and High-viscosity Preservation Solutions to Decrease the Incidence of Nonanastomotic Biliary Strictures After Liver Transplantation |
- Number of participants with primary non-function (PNF) for safety assessment of sequential perfusion [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]PNF is defined as non-life-sustaining function of the graft unexplained by vascular complications or rejection, leading to death or retransplantation within postoperative 7 days.
- Number of participants with nonanastomotic biliary strictures with a patent hepatic artery [ Time Frame: 5 years ] [ Designated as safety issue: No ]nonanastomotic biliary strictures secondary to hepatic arterial thrombosis or stenosis will be excluded from calculation.
- Number of participants with initial poor function (IPF) [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]IPF is defined as a delayed function restoration with serum AST level greater than 2,000 U/L and prothrombin time greater than 16 seconds postoperative days 2 to 7.
| Enrollment: | 141 |
| Study Start Date: | July 2004 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: sequential perfusion
sequential perfusion of liver grafts with low-viscosity improved Ross solution and high-viscosity UW solution.
|
Procedure: sequential perfusion with ipv Ross solution and UW solution
Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
|
|
Placebo Comparator: sole perfusion
sole perfusion of liver grafts with high-viscosity UW solution only
|
Procedure: sole perfusion with UW solution
Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
|
Detailed Description:
The exact etiology of nonanastomotic biliary strictures (NAS) with a patent hepatic artery after liver transplantation remains unclear so far. Microangiopathy is strongly suspected to be involved in the etiology, so sufficient flushing of peribiliary plexus (PBP) which directly nourishes the donor biliary tree may be pivotal to prevent NAS with a patent hepatic artery.
Solution of University of Wisconsin (UW solution) is a standard for liver graft flushing, but accused of high viscosity and hyperaggregation effect on erythrocytes by ingredient hydroxyethyl starch as well as initial vasoconstriction by high potassium content, which together constitutes a hindrance to solution penetration and thorough flushing of liver microcirculation including PBP. Several studies have revealed the relationship of high viscosity of UW solution with the development of NAS.
The investigators, therefore, have hypothesized that sequential perfusion with low-viscosity and high-viscosity preservation solutions might improve the patency of PBP in contrast with conventional sole perfusion with high-viscosity UW solution, and as a result, the incidence of NAS with a patent hepatic artery after liver transplantation would be significantly decreased.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age≥18 years
- ability to provide written informed consent prior to study entry
- receiving a whole liver graft
- primary transplantation
Exclusion Criteria:
- participant in other clinical trials
- fulminant liver failure as the cause of transplantation
- primary biliary cirrhosis, autoimmune hepatitis or primary sclerosing cholangitis as primary liver disease
- retransplantation
- non-liver organ(s) failure prior to study entry
- donor/recipient ABO-blood-group-incompatibility
Contacts and Locations| China, Shanghai | |
| Shanghai First People's Hospital | |
| Shanghai, Shanghai, China, 200080 | |
| Study Director: | Zhi-Hai Peng, Prof. | Shanghai First People's Hospital |
More Information
Publications:
| Responsible Party: | Zhi-Hai Peng/ vice-president of Shanghai First People's Hospital, Shanghai First People's Hospital |
| ClinicalTrials.gov Identifier: | NCT01271179 History of Changes |
| Other Study ID Numbers: | SFPH04618 |
| Study First Received: | December 30, 2010 |
| Last Updated: | January 5, 2011 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Shanghai Jiao Tong University School of Medicine:
|
orthotopic liver transplantation preservation solution peribiliary plexus nonanastomotic biliary strictures primary non-function |
Additional relevant MeSH terms:
|
Cholestasis Constriction, Pathologic Bile Duct Diseases |
Biliary Tract Diseases Digestive System Diseases Pathological Conditions, Anatomical |
ClinicalTrials.gov processed this record on May 23, 2013